Using FNAC and Flow Cytometry to Classify Non-Hodgkin Lymphoma
Author Information
Author(s): Pranab Dey, Amir Thasneem, Aisha Al Jassar, Salem Al Shemmari, Sanjay Jogai, Ganapathi Bhat, Aisha Al Quallaf, Zahia Al Shammari
Primary Institution: Kuwait Cancer Control Center, Suwaikh, Kuwait
Hypothesis
Can fine needle aspiration cytology (FNAC) combined with flow cytometric immunophenotyping (FCI) accurately classify non-Hodgkin lymphoma (NHL) according to WHO standards?
Conclusion
FNAC combined with FCI is effective in accurately subclassifying non-Hodgkin lymphoma according to WHO classification.
Supporting Evidence
- Flow cytometry was performed in 45 out of 48 cases, showing a high success rate.
- 79% of NHL cases were successfully subclassified according to WHO classification.
- Light chain restriction was demonstrated in 75% of B-NHL cases.
Takeaway
Doctors can use a special needle to take a tiny sample from a lump and then use tests to figure out what type of lymphoma it is, which helps in treating it better.
Methodology
The study involved FNAC and FCI on NHL cases over five years, analyzing cytologic findings and FCI data together.
Limitations
The study may not generalize to all NHL cases, and FCI was inadequate in some instances.
Participant Demographics
34 male and 14 female patients, ages 6 to 78.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website